



10 July 2007

## **Optiscan product sales 2006/07 \$5.49M**

- *88 systems shipped to Pentax*
- *Product sales revenue up 72% on pcp*

**Melbourne:** Optiscan product sales revenue for the year ended 30 June 2007 (unaudited) amounted to \$5.49M.

Sales included the export to Pentax of 88 endo-microscope systems and associated miniaturised scanners, as well as initial sales of FIVE1 instruments for the research market.

Optiscan will include this information in a presentation to be released tomorrow, and a copy has been posted on the company's website.

Full details of the financial results for the year ended 30 June 2007 will be released in late August, when the audit has been completed.

### **Background**

Optiscan is a global leader in microscopic imaging technologies for medical markets.

Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Pentax has been licensed by Optiscan to use its patented miniaturised microscope technology in the US\$1.2Bn pa global flexible endoscope market.

Optiscan has also recently announced a collaboration with the Carl Zeiss Group in Germany for the use of its patented miniaturised microscope technology in rigid endoscopes in key Zeiss markets.

Further information:

Matthew Barnett, CEO  
Tel (613) 9538 3347  
matthewb@optiscan.com

Bruce Andrew, CFO  
Tel (613) 9538 3398  
brucea@optiscan.com